These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 17931155

  • 21. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC.
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [Abstract] [Full Text] [Related]

  • 22. Contribution of CpG motifs to the immunogenicity of DNA vaccines.
    Klinman DM, Yamshchikov G, Ishigatsubo Y.
    J Immunol; 1997 Apr 15; 158(8):3635-9. PubMed ID: 9103425
    [Abstract] [Full Text] [Related]

  • 23. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM, Klaschik S, Sato T, Tross D.
    Adv Drug Deliv Rev; 2009 Mar 28; 61(3):248-55. PubMed ID: 19272313
    [Abstract] [Full Text] [Related]

  • 24. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
    Harandi AM, Holmgren J.
    Curr Opin Investig Drugs; 2004 Feb 28; 5(2):141-5. PubMed ID: 15043387
    [Abstract] [Full Text] [Related]

  • 25. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ, Gursel I, Gursel M, Klinman DM.
    Curr Opin Mol Ther; 2004 Apr 28; 6(2):166-74. PubMed ID: 15195929
    [Abstract] [Full Text] [Related]

  • 26. Advances in vaccine adjuvants.
    Singh M, O'Hagan D.
    Nat Biotechnol; 1999 Nov 28; 17(11):1075-81. PubMed ID: 10545912
    [Abstract] [Full Text] [Related]

  • 27. Designing immune responses with genetic immunization and immunostimulatory DNA sequences.
    Thalhamer J, Leitner W, Hammerl P, Brtko J.
    Endocr Regul; 2001 Sep 28; 35(3):143-66. PubMed ID: 11674843
    [Abstract] [Full Text] [Related]

  • 28. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
    Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR.
    Expert Rev Vaccines; 2003 Apr 28; 2(2):219-29. PubMed ID: 12899573
    [Abstract] [Full Text] [Related]

  • 29. The immunophysiological impact of bacterial CpG DNA on the gut.
    Watson JL, McKay DM.
    Clin Chim Acta; 2006 Feb 28; 364(1-2):1-11. PubMed ID: 16153626
    [Abstract] [Full Text] [Related]

  • 30. Synthetic agonists of Toll-like receptors 7, 8 and 9.
    Agrawal S, Kandimalla ER.
    Biochem Soc Trans; 2007 Dec 28; 35(Pt 6):1461-7. PubMed ID: 18031246
    [Abstract] [Full Text] [Related]

  • 31. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
    Vollmer J, Krieg AM.
    Adv Drug Deliv Rev; 2009 Mar 28; 61(3):195-204. PubMed ID: 19211030
    [Abstract] [Full Text] [Related]

  • 32. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
    Mutwiri G, van Drunen Littel-van den Hurk S, Babiuk LA.
    Adv Drug Deliv Rev; 2009 Mar 28; 61(3):226-32. PubMed ID: 19162103
    [Abstract] [Full Text] [Related]

  • 33. [Immunostimulatory sequence and DNA vaccine].
    Zhao S, Zhu YC.
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Apr 30; 22(2):122-5. PubMed ID: 15281461
    [No Abstract] [Full Text] [Related]

  • 34. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
    Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S.
    Nature; 2008 Feb 07; 451(7179):725-9. PubMed ID: 18256672
    [Abstract] [Full Text] [Related]

  • 35. Towards optimal design of second-generation immunomodulatory oligonucleotides.
    Kandimalla ER, Yu D, Agrawal S.
    Curr Opin Mol Ther; 2002 Apr 07; 4(2):122-9. PubMed ID: 12044033
    [Abstract] [Full Text] [Related]

  • 36. Innate immune recognition of, and regulation by, DNA.
    Ishii KJ, Akira S.
    Trends Immunol; 2006 Nov 07; 27(11):525-32. PubMed ID: 16979939
    [Abstract] [Full Text] [Related]

  • 37. Innate immune control of nucleic acid-based vaccine immunogenicity.
    Koyama S, Coban C, Aoshi T, Horii T, Akira S, Ishii KJ.
    Expert Rev Vaccines; 2009 Aug 07; 8(8):1099-107. PubMed ID: 19627190
    [Abstract] [Full Text] [Related]

  • 38. HBV-ISS (Dynavax).
    Sung JJ, Lik-Yuen H.
    Curr Opin Mol Ther; 2006 Apr 07; 8(2):150-5. PubMed ID: 16610768
    [Abstract] [Full Text] [Related]

  • 39. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
    Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S.
    J Med Chem; 2007 Dec 13; 50(25):6411-8. PubMed ID: 17988082
    [Abstract] [Full Text] [Related]

  • 40. Resiquimod and other immune response modifiers as vaccine adjuvants.
    Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP.
    Expert Rev Vaccines; 2007 Oct 13; 6(5):835-47. PubMed ID: 17931162
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.